Table 3.
Indicators | n a | Cut-off | Sensitivity | Specificity | AUC | 95% CI | p b |
---|---|---|---|---|---|---|---|
Dyspnea | 109 | 66.67 | 0.508 | 0.729 | 0.661 | 0.560–0.761 | .002** |
Fatigue | 108 | 66.67 | 0.683 | 0.542 | 0.691 | 0.593–0.789 | < .001** |
CRP (mg/dL) | 106 | 3.0 | 0.678 | 0.489 | 0.612 | 0.504–0.720 | .043* |
Alb (g/dL) | 106 | 2.5 | 0.593 | 0.638 | 0.604 | 0.496–0.713 | .060 |
NLR | 102 | 8.2 | 0.667 | 0.644 | 0.699 | 0.598–0.801 | < .001** |
*p < .05, **p < .01; aNumber of patients whose survival time data were available. bp value derived according to the receiver operating characteristic curve analysis. All QLQ-C15-PAL scale scores were linearly transformed, and the resultant scores ranged from 0 to 100. Alb albumin, AUC area under the curve, CI confidence interval, CRP C-reactive protein, NLR neutrophil-lymphocyte ratio, QLQ-C15-PAL European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 Palliative Care